Elliot Marseille

TL;DR: It is argued that reliance on WHO-CHOICE thresholds reduces the value of cost–effectiveness analyses and makes such analyses too blunt to be useful for most decision-making in the field of public health.

TL;DR: The cost effectiveness of HIVNET 012 was robust under a wide range of parameters in the sensitivity analysis, and in lower seroprevalence areas, when multidose regimens are not cost effective, nevirapine therapy could have a major public-health impact at a reasonable cost.

TL;DR: In settings in sub-Saharan Africa with high or moderate HIV prevalence among the general population, adult MC is likely to be a cost-effective HIV prevention strategy, even when it has a low coverage.

TL;DR: Large variations in estimated GDM prevalence are found, but direct comparison between countries is difficult due to different diagnostic strategies and subpopulations, and countries need to carefully assess the cost and health impact of scaling up GDM screening and management in order to identify the best policy option for their population.

TL;DR: It is shown that funding HAART at the expense of prevention means greater loss of life, and to maximise health benefits, the next major increments of HIV funding in sub-Saharan Africa should be devoted mainly to prevention and to some non-HAART treatment and care.